Cochrane · systematic review · CD006468
Anticoagulation for people with cancer and central venous catheters
Kahale, LA, Tsolakian, IG, Hakoum, MB, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
24
current version
GRADE rated
21
No studies
3
Included studies
NR
No studies 3 · 12.5%Ungraded 0 · 0%Very low 7 · 29.2%Low 12 · 50%Moderate 2 · 8.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 5 versionsLow‐molecular‐weight heparin (LMWH) compared to no LMWH for people with cancer and central venous catheters
Population: people with cancer with thrombosis prophylaxis and central venous catheters
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes ( Low‐molecular‐weight heparin (LMWH) vs no LMWH | no estimate extracted | NR | No studies |
All‐cause mortality (up to 3 months) Low‐molecular‐weight heparin (LMWH) vs no LMWH | RR 0.82 [0.53, 1.26] | 5 studies · 1236 participants | Low Downgraded: risk of bias |
Symptomatic catheter‐related thrombosis (up to 3 months) Low‐molecular‐weight heparin (LMWH) vs no LMWH | RR 0.43 [0.22, 0.81] | 5 studies · 1089 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Symptomatic catheter‐related thrombosis measured as asymptomatic catheter‐related thrombosis (up to 3 months) Low‐molecular‐weight heparin (LMWH) vs no LMWH | RR 0.95 [0.62, 1.46] | 5 studies · 1089 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Major bleeding (up to 3 months) Low‐molecular‐weight heparin (LMWH) vs no LMWH | RR 1.49 [0.06, 36.28] | 4 studies · 1018 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Minor bleeding (up to 3 months) Low‐molecular‐weight heparin (LMWH) vs no LMWH | RR 1.35 [0.62, 2.92] | 2 studies · 544 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Catheter‐related infection (up to 3 months) Low‐molecular‐weight heparin (LMWH) vs no LMWH | RR 0.97 [0.52, 1.79] | 2 studies · 474 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Thrombocytopenia (up to 3 months) Low‐molecular‐weight heparin (LMWH) vs no LMWH | RR 1.03 [0.8, 1.33] | 4 studies · 1002 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Vitamin K antagonist (VKA) compared to no VKA for people with cancer and central venous catheters
Population: people with cancer with thrombosis prophylaxis and central venous catheters
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes ( Vitamin K antagonist (VKA) vs no VKA | no estimate extracted | NR | No studies |
All‐cause mortality (up to 3 months) Vitamin K antagonist (VKA) vs no VKA | RR 0.99 [0.64, 1.55] | 4 studies · 701 participants | Low Downgraded: risk of bias |
Symptomatic catheter‐related thrombosis (up to 3 months) Vitamin K antagonist (VKA) vs no VKA | RR 0.61 [0.23, 1.64] | 4 studies · 1271 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Symptomatic catheter‐related thrombosis measured as asymptomatic catheter‐related thrombosis (up to 3 months) Vitamin K antagonist (VKA) vs no VKA | RR 0.61 [0.27, 1.4] | 2 studies · 384 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Major bleeding (up to 3 months) Vitamin K antagonist (VKA) vs no VKA | RR 7.14 [0.88, 57.78] | 2 studies · 1026 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Minor bleeding (up to 3 months) Vitamin K antagonist (VKA) vs no VKA | RR 0.69 [0.38, 1.26] | 2 studies · 1026 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Catheter‐related infection (3 months) Vitamin K antagonist (VKA) vs no VKA | RR 1.17 [0.74, 1.85] | 1 study · 88 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Premature CVC removal (3 months) Vitamin K antagonist (VKA) vs no VKA | RR 0.82 [0.3, 2.24] | 1 study · 88 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Low‐molecular‐weight heparin (LMWH) compared to vitamin K antagonist (VKA) for people with cancer and central venous catheters
Population: people with cancer with thrombosis prophylaxis and central venous catheters
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes ( Low‐molecular‐weight heparin (LMWH) vs vitamin K antagonist (VKA) | no estimate extracted | NR | No studies |
All‐cause mortality (up to 3 months) Low‐molecular‐weight heparin (LMWH) vs vitamin K antagonist (VKA) | RR 0.94 [0.56, 1.59] | 3 studies · 561 participants | Low Downgraded: risk of bias |
Symptomatic catheter‐related thrombosis (up to 3 months) Low‐molecular‐weight heparin (LMWH) vs vitamin K antagonist (VKA) | RR 1.83 [0.44, 7.61] | 2 studies · 327 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Symptomatic catheter‐related thrombosis measured as asymptomatic catheter‐related thrombosis (up to 3 months) Low‐molecular‐weight heparin (LMWH) vs vitamin K antagonist (VKA) | RR 1.61 [0.75, 3.46] | 2 studies · 317 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Pulmonary embolism (up to 3 months) Low‐molecular‐weight heparin (LMWH) vs vitamin K antagonist (VKA) | RR 1.7 [0.74, 3.92] | 2 studies · 327 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Major bleeding (up to 3 months) Low‐molecular‐weight heparin (LMWH) vs vitamin K antagonist (VKA) | RR 3.11 [0.13, 73.11] | 2 studies · 289 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Minor bleeding (up to 3 months) Low‐molecular‐weight heparin (LMWH) vs vitamin K antagonist (VKA) | RR 0.95 [0.2, 4.61] | 1 study · 234 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Thrombocytopenia (up to 3 months)n Low‐molecular‐weight heparin (LMWH) vs vitamin K antagonist (VKA) | RR 1.69 [1.2, 2.39] | 2 studies · 327 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |